GH1 and Hodgkins lymphoma: Recent reports from the Safety and Appropriateness of Growth Hormone Treatments in Europe (SAGhE), the European cohort study across 23,984 patients in eight European countries indicate a distinct risk of cancer, especially Hodgkin’s lymphoma and meningioma[72], in pediatric GHD patients “with previous history of cancer” and treated with GH in childhood[73].